×
Vaxxinity Common Stock Net 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity common stock net from 2020 to 2023. Common stock net can be defined as the value of common equity ownership.
View More
Vaxxinity Common Stock Net 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity common stock net from 2020 to 2023. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$139.4B
Bristol Myers Squibb (BMY)
$115.2B
Gilead Sciences (GILD)
$114.5B
Vertex Pharmaceuticals (VRTX)
$104.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$78.6B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$37.4B
Alnylam Pharmaceuticals (ALNY)
$30.1B
BioNTech SE (BNTX)
$27.6B
Biogen (BIIB)
$21.9B
Illumina (ILMN)
$20.8B
BeiGene (ONC)
$18B
Moderna (MRNA)
$16.2B
Genmab (GMAB)
$13.9B
Incyte (INCY)
$13.4B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.5B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.4B
Exact Sciences (EXAS)
$10.5B
Vaxcyte (PCVX)
$10.4B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8B